Document:

REGISTRATION RIGHTS AGREEMENT

         This Registration Rights Agreement (this "Agreement") is by and between
TRINITY MEDICAL GROUP USA, INC., a Delaware  Corporation  (the  "Company"),  and
___________________________ (the "Holder") dated as of this _____ day of ______,
1999.

                              W I T N E S S E T H:

         WHEREAS,  the  Company  has issued  Holder a Note for  $5,000  with 10%
interest per annum convertible at the election of the holder between October 15,
1999 and December 31, 1999 or by election of the Company after December 31, 1999
to 5,000 shares of company  common  stock,  par value $.001 per share  purchased
pursuant to the Private Placement  Memorandum,  dated July 21, 1999 (the "Common
Stock"); and

         WHEREAS,   the  Company   desires  to  grant  to  the  Holder   certain
registration rights in respect of the issuance or resale of the shares of Common
Stock.

         NOW,  THEREFORE,  in  consideration  of the  premises  and  the  mutual
covenants  contained  herein,  and other good and  valuable  consideration,  the
receipt and  sufficiency  of which is hereby  acknowledged,  the parties  hereto
agree as follows:

                                   ARTICLE ONE
                          Registration Rights Agreement

         SECTION  1.1  Registration  Rights  Available.  The  Company  agrees to
provide  Holder with respect to the shares of Common Stock  converted by Holder,
pursuant to the Private Placement Memorandum,  dated September 15, 1999, and any
other securities  issued or issuable at any time or from time to time in respect
of  the  shares  of  Common   Stock  upon  a  stock   split,   stock   dividend,
recapitalization or other similar event involving the Company (collectively, the
"Securities"):  one demand secondary offering by means registration  pursuant to
the  Securities  Act of 1933,  as  amended  ("Securities  Act"),  subject to the
provisions  of this  Agreement  (the  demand  registration  right is referred to
herein as the "Registration Right").

         SECTION 1.2 Demand Registration.  With respect to Holder's right to one
demand registration pursuant to Section 1.1 (a), the parties agree as follows:

         (a) Holder shall provide  written notice to the Company  indicating his
intention to exercise  the demand  registration  right on or after  December 31,
1999, and on or before  September 15, 2000. The Company shall  promptly,  and in
any event  within 90 days of  receiving  notice from the  Holders,  use its best
efforts to file with the Securities and Exchange  Commission (the  "Commission")
and cause to become  effective,  a registration  statement on  appropriate  form
relating to the offer and sale of the Common Stock by Holder.  The Company shall
use its best efforts to file a registration  statement for the demand  secondary
offering  requested under Section 1.1. The Company agrees to provide Holder with
notice of the filing of such registration and of the filing of any amendments or
supplements thereto.

         (b) The  Company  agrees to maintain  such  registration  statement  in
effect for the maximum period allowable under the regulations promulgated by the
Commission then in effect.

         (c) In any offering  pursuant to this Section that becomes effective in
which the Holder  participates,  the Company  shall use its best efforts to keep
available  to the  Holder a  prospectus  meeting  the  requirements  of  Section
10(a)(3) of the Securities  Act and shall file all  amendments  and  supplements
under the Securities Act required for that purpose.  In any offering pursuant to
this Section the Company will, as soon as  practicable,  use its best efforts to
effect such  registration and use its best efforts to effect such  qualification
and  compliance  as may be so requested  and as would permit or  facilitate  the
distribution of such Securities,  including,  without  limitation,  registration
under the Securities Act,  appropriate  qualifications under applicable blue-sky
or  other  state  securities  laws,   appropriate   compliance  with  any  other
governmental requirements and listing on a national securities exchange on which
the Common Stock is then listed or inter-dealer quotation system.

<PAGE>

         SECTION 1.3  Registration  Procedure.  With respect to the Registration
Right, the following provisions shall apply:

         (a)  Holder  shall be  obligated  to  furnish  to the  Company  and the
underwriters (if any) such information regarding the Securities and the proposed
manner of distribution of the Securities as the Company and the underwriters (if
any) may  request in writing and as shall be  required  in  connection  with any
registration, qualification or compliance referred to herein and shall otherwise
cooperate with the Company and the underwriters (if any) in connection with such
registration, qualification or compliance.

         (b) With a view to making  available  the benefits of certain rules and
regulations  of the  Commission  which  may at any time  permit  the sale of the
Restricted  Securities  (used herein as defined in Rule 144 under the Securities
Act) to the public  without  registration,  the  Company  agrees to use its best
lawful efforts to:

                  (i) Make and keep public information available, as those terms
         are understood and defined in Rule 144 under the Securities Act, at all
         times during which the Company is subject to the reporting requirements
         of the  Securities  Exchange  Act of 1934,  as amended  (the  "Exchange
         Act");

                  (ii) File with the  Commission  in a timely manner all reports
         and other  documents  required of the Company under the  Securities Act
         and the  Exchange Act (at all times during which the Company is subject
         to such reporting requirements); and

                  (iii) So long as Holder  owns any  Restricted  Securities,  to
         furnish to Holder  forthwith  upon  request a written  statement by the
         Company as to its compliance  with the reporting  requirements  of said
         Rule 144 and with regard to the Securities Act and the Exchange Act (at
         all times  during  which  the  Company  is  subject  to such  reporting
         requirements),  a copy of the most recent annual or quarterly report of
         the Company,  and such other  reports and  documents of the Company and
         other information in the possession of or reasonably  obtainable by the
         Company as Holder may reasonably request in availing  themselves of any
         rule or regulation of the Commission  allowing  Holder to sell any such
         securities without registration.

         (c) The Company  agrees  that it will  furnish to Holder such number of
prospectuses,   offering   circulars   or  other   documents   incident  to  any
registration,  qualification or compliance referred to herein as provided or, if
not otherwise provided, as the Holder from time to time may reasonably request.

         (d) Except for the legal fees of Holder and any sales  commissions that
may be paid by Holder,  all expenses of any registrations  permitted pursuant to
this  Agreement and of all other  offerings by the Company  (including,  but not
limited to, the expenses of any qualifications under the blue-sky or other state
securities laws and compliance with  governmental  requirements of preparing and
filing any post-effective amendments required for the lawful distribution of the
Securities  to the public in  connection  with such  registration,  of supplying
prospectuses,  offering  circulars  or  other  documents)  will  be  paid by the
Company.

         (e) The Registration Right of this Agreement,  subject to the terms and
conditions hereof, shall be available to any subsequent holder of the Securities
owned by Holder. Each subsequent holder entitled to the Registration Right under
this  Agreement  shall be bound by the terms and subject to the  obligations  of
this Agreement as though it were an original signatory hereto.

                                   ARTICLE TWO
                                 Indemnification

         SECTION  2.1  Indemnification  by  the  Company.  In the  event  of any
registration  of the  Securities  of the Company under the  Securities  Act, the
Company  agrees to indemnity and hold harmless  Holder and each other person who
participates  as an  underwriter  in the  offering  or sale  of such  securities
against any and all  claims,  demands,  losses,  costs,  expenses,  obligations,
liabilities,  joint or several, damages, recoveries and deficiencies,  including
interest,  penalties and  attorneys'  fees  (collectively,  "Claims"),  to which
Holder or underwriter  may become subject under the Securities Act or otherwise,
insofar  as such  Claims  (or  actions  or  proceedings,  whether  commenced  or
threatened,  in  respect  thereof)  arise  out of or  are  based  on any  untrue
statement or alleged  untrue  statement of any  material  fact  contained in any
registration statement under which Holder's Securities were

<PAGE>

registered  under  the  Securities  Act,  any  preliminary   prospectus,   final
prospectus  or  summary  prospectus  contained  therein,  or  any  amendment  or
supplement  thereto,  or any  omission or alleged  omission  to state  therein a
material fact required to be stated  therein or necessary to make the statements
therein not  misleading,  and the Company  will  reimburse  Holder and each such
underwriter for any legal or any other expenses  reasonably  incurred by them in
connection  with  investigating  or  defending  any such  Claim  (or  action  or
proceeding in respect thereof); provided that the Company shall not be liable in
any such case to the  extent  that any such Claim (or  action or  proceeding  in
respect  thereof) or expense arises out of or is based on an untrue statement or
alleged  untrue   statement  or  omission  or  alleged  omission  made  in  such
registration  statement,  any such  preliminary  prospectus,  final  prospectus,
summary  prospectus,  amendment or  supplement  in reliance on and in conformity
with written  information  furnished to the Company  through an instrument  duly
executed by Holder  specifically  stating that it is for use in the  preparation
thereof.  Such indemnity shall remain in full force and effect regardless of any
investigation  made by or on behalf of Holder or any such  underwriter and shall
survive the transfer of the Securities by Holder.

         SECTION 2.2  Indemnification by Holder.  The Company may require,  as a
condition  to including  the  Securities  in any  registration  statement  filed
pursuant to this Agreement,  that the Company shall have received an undertaking
satisfactory  to it from  Holder,  to indemnify  and hold  harmless (in the same
manner and to the same  extent as set forth in Section  2.1) the  Company,  each
director of the Company,  each officer of the Company and each other person,  if
any, who controls the Company,  within the meaning of the  Securities  Act, with
respect to any statement or alleged statement in or omission or alleged omission
from such registration statement,  any preliminary prospectus contained therein,
or any amendment or supplement  thereto,  if such statement or alleged statement
or omission or alleged  omission was made in reliance on and in conformity  with
written information furnished to the Company through an instrument duly executed
by Holder  specifically  stating that it is for use in the  preparation  of such
registration  statement,   preliminary  prospectus,  final  prospectus,  summary
prospectus, amendment or supplement.  Notwithstanding the foregoing, the maximum
liability  hereunder  which any  holder  shall be  required  to suffer  shall be
limited to the net  proceeds  to such Holder  from the  Securities  sold by such
Holder in the offering.  Such  indemnity  shall remain in full force and effect,
regardless of any investigation  made by or on behalf of the Company or any such
director,  officer or  controlling  person and shall survive the transfer of the
Securities by Holder.

         SECTION  2.3  Notices  of Claims,  etc.  Promptly  after  receipt by an
indemnified  party of notice of the  commencement  of any  action or  proceeding
involving a Claim referred to in this Article Two, such indemnified  party will,
if a claim in respect thereof is to be made against an indemnifying  party, give
written notice to the latter of the  commencement of such action,  provided that
the failure of any indemnified party to give notice as provided herein shall not
relieve the indemnifying party of its obligations under this Article Two, except
to the extent that the indemnifying party is actually prejudiced by such failure
to give  notice.  In case any such  action is brought  against  an  indemnifying
party,  unless in such  indemnified  party's  reasonable  judgment a conflict of
interest between such indemnified and indemnifying  parties may exist in respect
of such Claim, the indemnifying party shall be entitled to participate in and to
assume the defense thereof,  jointly with any other indemnifying party similarly
notified to the extent that it may wish, with counsel reasonably satisfactory to
such indemnified  party,  and after notice from the  indemnifying  party to such
indemnified  party  of its  election  so to  assume  the  defense  thereof,  the
indemnifying  party shall not be liable to such indemnified  party for any legal
or other  expenses  subsequently  incurred by the latter in connection  with the
defense thereof other than reasonable  costs of  investigation.  No indemnifying
party shall,  without the consent of the indemnified party,  consent to entry of
any  judgment  or  enter  into  any  settlement  that  does  not  include  as an
unconditional  term  thereof  the giving by the  claimant or  plaintiff  to such
indemnified party of a release from all liability in respect of such Claim.

         SECTION 2.4 Indemnification  Payments. The indemnification  required by
this Article shall be made by periodic payments of the amount thereof during the
course of the  investigation  or  defense,  as and when  bills are  received  or
expense, loss, damage or liability is incurred.

                                  ARTICLE THREE
                                  Miscellaneous

         SECTION  3.1  Consent  to  Amendments.  Except as  otherwise  expressly
provided herein,  the provisions of this Agreement may be amended or waived only
by the  written  agreement  of the  Company and the Holder of 51% or more of the
shares of Common  Stock and shall be effective  only to the extent  specifically
set forth in such writing.

<PAGE>

         SECTION 3.2 Term of the Agreement.  This Agreement shall terminate with
respect to Holder on the  earlier  to occur of (i) the  Securities  having  been
registered as provided in Article One or (ii) September 15, 2000.

         SECTION 3.3  Successors  and  Assigns.  Except as  otherwise  expressly
provided herein, all covenants and agreements  contained in this Agreement by or
on behalf of any of the parties hereto are  transferable and will bind and inure
to the benefit of the respective  successors and assigns of the parties  hereto,
but only if so expressed in writing.

         SECTION 3.4  Severability.  Whenever  possible,  each provision of this
Agreement  will be  interpreted  in such a manner as to be  effective  and valid
under  applicable  law,  but if any  provision  of this  Agreement is held to be
prohibited  by  or  invalid  under   applicable  law,  such  provision  will  be
ineffective  only to the  extent  of such  prohibition  or  invalidity,  without
invalidating the remainder of this Agreement.

         SECTION 3.5 Delays or Omissions. No failure to exercise or delay in the
exercise  of any  right,  power or remedy  accruing  to Holder on any  breach or
default of the Company under this Agreement  shall impair any such right,  power
or  remedy  nor  shall it be  construed  to be a waiver  of any such  breach  or
default.

         SECTION 3.6 Remedies Cumulative.  All remedies under this Agreement, or
by law or otherwise  afforded to any party hereto  shall be  cumulative  and not
alternative.

         SECTION 3.7  Descriptive  Headings.  The  descriptive  headings of this
Agreement are inserted for convenience only and do not constitute a part of this
Agreement.  Unless  clearly  denoted  otherwise,  any  reference  to Articles or
Sections  contained  herein  shall  be to  the  Articles  or  Sections  of  this
Agreement.

         SECTION 3.8  Notices.  Any notices  required  or  permitted  to be sent
hereunder  shall be  delivered  personally  or mailed,  certified  mail,  return
receipt requested, to the following addresses,  and shall be deemed to have been
received on the day of personal  delivery or within  three  business  days after
deposit in the mail, postage prepaid:

         If to the Company, to:
                                            James Namnath
                                            Trinity Medical Group USA, Inc.
                                            55 Shaver Street Suite 320
                                            San Rafael, CA 94901
                  If to Holder, to:

                  -------------------------------
                  -------------------------------
                  -------------------------------

         SECTION 3.9  Governing  Law. The  validity,  meaning and effect of this
Agreement  shall be  determined  in  accordance  with  the laws of the  State of
California applicable to contracts made and to be performed in that state.

         SECTION  3.10 Final  Agreement.  This  Agreement,  together  with those
documents  expressly referred to herein,  constitutes the final agreement of the
parties  concerning  the matters  referred to herein,  and  supersedes all prior
agreements and understandings.

         SECTION 3.11 Execution in Counterparts.  This Agreement may be executed
in any number of  counterparts,  each of which when so  executed  and  delivered
shall be deemed an original, and such counterparts together shall constitute one
instrument.

         The parties  hereto have executed  this  Agreement as of the date first
set forth above.

                                    COMPANY:
                                    TRINITY MEDICAL GROUP USA, INC.

                                    By /s/ James S. Namnath
                                      ----------------------------------------
                                      James S. Namnath, Ph.D.

                                    HOLDER:

                                      ------------------------------------------FORM OF NOTE PAYABLE                                                 APPENDIX C

THIS NOTE HAS NOT BEEN REGISTERED  UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
AND IS  TRANSFERABLE  ONLY UPON THE  CONDITIONS  SPECIFIED IN THE NOTE AGREEMENT
REFERRED TO HEREIN.

                                 PROMISSORY NOTE

$5,000                  San Rafael, California         Date:________ _____, 1999

         FOR VALUE RECEIVED,  the  undersigned,  Trinity Medical Group USA, Inc.
("Maker"),  hereby  promises  to pay to the  order  of  ________________________
("Payee"),  the principal sum of Five Thousand and no/100 Dollars  ($5,000),  in
lawful  money in United  States of  America,  which  shall be legal  tender,  in
payment  of all debts and dues,  public  and  private,  at the time of  payment,
bearing interest and payable as provided herein.

         Interest on the unpaid  balance of this Note shall  accrue at a rate of
10% per  annum;  provided,  however,  that such  interest  shall not  exceed the
Maximum Rate as hereinafter  defined.  All past-due principal and interest shall
bear interest at the maximum rate permitted by applicable law.  Interest will be
computed on the basis of a 360-day year of twelve 30-day months.

         All interest to be paid on this Note shall be payable, at the option of
the  Maker,  in either  cash or in shares of Maker  common  stock.  The value of
Maker's  common  stock shall be the Fair  Market  Value of the shares of Maker's
common stock, as defined in this Note.

         The "Fair  Market  Value" of a share of Maker  common stock on any date
shall be (i) the closing sales price on the immediately  preceding  business day
of a share of  Maker  common  stock  as  reported  on the  principal  securities
exchange on which  shares of Maker  common  stock are then listed or admitted to
trading or (ii) if not so  reported,  the  average of the  closing bid and asked
prices for a share of Maker common stock on the immediately  preceding  business
day as  quoted on the  National  Association  of  Securities  Dealers  Automated
Quotation System ("Nasdaq") or (iii) if not quoted on Nasdaq, the average of the
closing bid and asked  prices for a share of Maker common stock as quoted by the
National  Association of Securities  Dealers' OTC Bulletin Board System.  If the
price of a share of Maker common stock shall not be so reported, the Fair Market
Value of a share of Maker common stock shall be  determined by the Maker's Board
of Directors in its absolute discretion. In no event shall the Fair Market Value
of any share of Maker common stock be less than its par value.

         The principal amount and accrued interest of this Note shall be due and
payable on August, 30, 2001, provided however,  the principal amount and accrued
interest of this Note shall be due and payable  immediately  upon the occurrence
of either of the following  events:  (i) a Change in Control of Trinity  Medical
Group USA,  Inc., as defined in this Note,  or (ii) the  completion of an equity
financing  which raises in the aggregate at least  $250,000,  in the form of one
equity  transaction or in the form of a series of equity  transactions  within a
six month period.  The Note may be renewed for additional  thirty day periods at
the option of the holder.

         For the  purpose  of this  Note,  "Change  in  Control"  shall mean the
occurrence of any of the following events:

         (i)      any person  becomes,  after the issue  date of this Note,  the
                  "beneficial owner" (as defined in Rule 13d-3 promulgated under
                  the  Securities  Exchange Act of 1934,  as amended  ("Exchange
                  Act")),  directly or  indirectly,  of  securities of the Maker
                  representing  30% or more of the combined  voting power of the
                  Maker's  then  outstanding  securities,  unless  the  Board of
                  Directors of the Maker (as  constituted  immediately  prior to
                  such  Change  in  Control)  determines  in its  sole  absolute
                  discretion that no Change in Control has occurred;

         (ii)     Individuals who constitute the Board of Directors of the Maker
                  on the  issue  date of this Note  cease,  for any  reason,  to
                  constitute  at least a majority of the Board of  Directors  of
                  the  Maker;  provided,  however,  that any  person  becoming a
                  director  subsequent  to the  issue  date of this Note who was
                  nominated  for  election  by at  least  66%  of the  Board  of
                  Directors  of the Maker as

                                      C-1

<PAGE>

                  constituted  on the issue  date of this Note  (other  than the
                  nomination of an individual whose initial assumption of office
                  is in connection with an actual or threatened election contest
                  relating  to the  election  of the Board of  Directors  of the
                  Maker, as such terms are used in Rule 14a-11 of Regulation 14A
                  promulgated  under the Exchange Act) shall be, for purposes of
                  this Note,  considered  a member of the Board of  Directors of
                  the Maker as constituted on the issue date of this Note; or

         (iii)    the Board of Directors of the Maker determines in its sole and
                  absolute discretion that there has been a Change in Control of
                  the Maker.

         This Note may be prepaid in whole or in part, at any time and from time
to time, without premium or penalty.

         If any payment of  principal  or interest on this Note shall become due
on a Saturday,  Sunday or any other day on which national banks are not open for
business, such payment shall be made on the next succeeding business day.

         The  indebtedness  evidenced by this Note is unsecured and  subordinate
and  junior in right of  payment  to the  prior  payment  in full of all  senior
indebtedness (however defined in any debt instrument).

         Notwithstanding  anything  to the  contrary  in this  Note or any other
agreement entered into in connection herewith, whether now existing or hereafter
arising and whether  written or oral,  it is agreed  that the  aggregate  of all
interest  and  any  other  charges  constituting  interest,  or  adjudicated  as
constituting  interest,  and contracted for, chargeable or receivable under this
Note or  otherwise  in  connection  with this loan  transaction,  shall under no
circumstances exceed the Maximum Rate. In the event the maturity of this Note is
accelerated  by reason of an Event of Default under this Note,  other  agreement
entered into in  connection  herewith or therewith,  by voluntary  prepayment by
Maker or otherwise, then earned interest may never include more than the Maximum
Rate,  computed from the dates of each advance of the loan proceeds  outstanding
until  payment.  If from any  circumstance  any  holder of this Note  shall ever
receive interest or any other charges constituting  interest,  or adjudicated as
constituting  interest,  the amount, if any, which would exceed the Maximum Rate
shall be applied to the  reduction of the  principal  amount owing on this Note,
and not to the payment of interest;  or if such excessive  interest  exceeds the
unpaid balance of principal hereof,  the amount of such excessive  interest that
exceeds the unpaid  balance of principal  hereof shall be refunded to Maker.  In
determining  whether or not the  interest  paid or payable  exceeds  the Maximum
Rate, to the extent  permitted by applicable law (i) any  non-principal  payment
shall be  characterized  as an expense,  fee or premium rather than as interest;
and (ii) all interest at any time contracted for, charged, received or preserved
in connection  herewith  shall be amortized,  prorated,  allocated and spread in
equal parts  during the period of the full  stated  term of this Note.  The term
"Maximum  Rate" shall mean the maximum  rate of interest  allowed by  applicable
federal or state law.

         Except as  provided  herein,  Maker and any  sureties,  guarantors  and
endorsers of this Note jointly and severally waive demand,  presentment,  notice
of  nonpayment  or  dishonor,   notice  of  intent  to  accelerate,   notice  of
acceleration, diligence in collecting, grace, notice and protest, and consent to
all  extensions  without  notice for any  period or periods of time and  partial
payments, before or after maturity,  without prejudice to the holder. The holder
shall similarly have the right to deal in any way, at any time, with one or more
of the foregoing  parties  without  notice to any other party,  and to grant any
such party any extensions of time for payment of any of said indebtedness, or to
grant any other  indulgences  or forbearance  whatsoever,  without notice to any
other party and without in any way affecting the personal liability of any party
hereunder.  If any  efforts  are made to  collect  or  enforce  this Note or any
installment due hereunder,  the undersigned  agrees to pay all collection  costs
and fees, including reasonable attorney's fees.

         This Note shall be construed and enforced under and in accordance  with
the laws of the State of California.

         IN WITNESS WHEREOF, Maker has duly executed this Note as of the day and
year first above written.

                                                 TRINITY MEDICAL GROUP USA, INC.

                                                 By /s/ James S. Namnath
                                                   -----------------------------
                                                   James S. Namnath, Ph.D.

                                      C-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]